ClinicalTrials.gg
TerminatedNCT04508023PREVENT-HDUpdated Jul 18, 2023Results posted

A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

A Phase 3 interventional study of Rivaroxaban and Placebo in Coronavirus Disease 2019 (COVID-19), sponsored by Janssen Research & Development, LLC. Terminated at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-18.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was terminated prematurely due to enrollment challenges.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,284
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing rivaroxaban in COVID-19 — none open to participants now, none under way, none of them phase 3. Rivaroxaban · COVID-19.

Enrollment
2nd of 11
1,284 · median 497
Started
2020
with 10 others
Phase 3
3 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
1 of 11
Janssen Research & Development, LLC

Among the 11 studies testing rivaroxaban in COVID-19, this one is the 2nd largest by enrollment, is one of 11 that started in 2020, is one of 3 in phase 3, and was the 7th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

None of the 11 studies testing rivaroxaban in COVID-19 is open now. The open studies under COVID-19, anywhere →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing rivaroxaban in COVID-19 as a file.
02

Study summary

The purpose of this study is to evaluate whether rivaroxaban reduces the risk of a composite endpoint of major venous and arterial thrombotic events, all-cause hospitalization, and all-cause mortality compared with placebo in outpatients with acute, symptomatic Coronavirus Disease 2019 (COVID-19) Infection.

03

Conditions studied

  • Coronavirus Disease 2019 (COVID-19)

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Coronavirus Disease 2019 (COVID-19) positive diagnosis by locally obtained viral diagnostic test (example, polymerase chain reaction [PCR]). This may be nasal swab or saliva test or other available technology to demonstrate current infection
  • Confirm that participant is known to health system, with at least 1 contact in electronic medical records (EMR) prior to screening
  • Symptoms attributable to COVID-19 (example, fever, cough, loss of taste or smell, muscle aches, shortness of breath, fatigue)
  • Initial treatment plan does not include hospitalization
  • Presence of at least 1 additional risk factor: a) age more than or equal to (>=) 60 years; b) prior history of VTE; c) history of thrombophilia; d) history of coronary artery disease (CAD); e) history of peripheral artery disease (PAD); f) history of cerebrovascular disease or ischemic stroke; g) history of cancer (other than basal cell carcinoma) h) history of diabetes requiring medication; i) history of heart failure; j) (BMI) greater than or equal to (>=) 35 kilogram per meter square (kg/m\^2); k) D-dimer greater than (>) for local laboratory (within 2 weeks of the date of the COVID-19 test and prior to randomization)

Exclusion criteria

Exclusion Criteria:

  • Increased risk of bleeding such as a) significant bleeding in the last 3 months; b) active gastroduodenal ulcer in the last 3 months; c) history of bronchiectasis or pulmonary cavitation; d) need for dual antiplatelet therapy or anticoagulation; e) prior intracranial hemorrhage, f) known severe thrombocytopenia g) active cancer and undergoing treatment
  • Any illness or condition that in the opinion of the investigator would significantly increase the risk of bleeding (example recent trauma, recent surgery, severe uncontrolled hypertension, gastrointestinal cancer, renal failure requiring dialysis, severe liver disease, known bleeding diathesis)
  • Known allergies, , or intolerance to rivaroxaban or its
  • Positive COVID-19 antibody or serology test after 2-week period of acute, symptomatic COVID-19 infection
  • Known diagnosis of triple positive (positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies) antiphospholipid syndrome
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,284 participants (actual)

Study arms

  • Experimental
    Rivaroxaban

    Participants will receive rivaroxaban 10 milligram (mg) tablet orally once daily for 35 Days along with standard of care treatment (SOC).

    Drug: Rivaroxaban · Other: Standard of Care (SOC)

  • Placebo comparator
    Placebo

    Participants will receive matching placebo tablet orally once daily for 35 Days along with SOC.

    Other: Placebo · Other: Standard of Care (SOC)

Interventions

  • Participants will receive rivaroxaban 10 mg tablet orally once daily.

    Also known as: JNJ-39039039, BAY 59-7939

  • OtherPlacebo

    Participants will receive matching placebo tablet orally once daily.

  • OtherStandard of Care (SOC)

    SOC treatment will be determined by the investigator based on local practice and consists of supportive care.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Time to First Occurrence of Primary Efficacy Composite Endpoint

    Number of participants with time to first occurrence of primary efficacy composite endpoint were reported. Time to first occurrence of primary efficacy composite endpoint is defined as time from randomization to first occurrence of any component of the primary endpoint. The components were: symptomatic venous thromboembolism (VTE), myocardial infarction (MI), ischemic stroke, acute limb ischemia, non-central nervous system (non-CNS) systemic embolization, all-cause hospitalization, and all-cause mortality.

    Time frame: Up to Day 35

  2. Number of Participants With Time to First Occurrence of The Principle Safety Outcome (Fatal Bleeding and Critical Site Bleeding) Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

    Number of participants with time to first occurrence of the principle safety outcome (fatal bleeding and critical site bleeding) based on a Modification of the ISTH criteria were reported. Fatal bleeding is defined as any bleeding event that leads to fatal outcome. Critical site bleeding defined as any bleeding event that occurred at critical site such as intracranial, intra-spinal, intraocular, pericardial, intra-articular, intra-muscular with compartment syndrome, retroperitoneal.

    Time frame: Up to Day 35

Secondary outcomes

  1. Number of Participants With Time to the First Occurrence of Secondary Efficacy Outcomes

    Number of participants with time to the first occurrence of secondary efficacy outcomes which included thrombotic events (symptomatic VTE, myocardial infarction, ischemic stroke, acute limb ischemia, non-CNS systemic embolization), emergency room (ER) visit, all-cause mortality, all-cause hospitalization, any thrombotic outcome and all-cause mortality, and any thrombotic outcome and all-cause hospitalization, were reported.

    Time frame: From Day 1 up to Day 35

  2. Number of Participants With Time to First Occurrence of Major Bleeding Based on a Modification of the ISTH Criteria

    Number of participants with time to first occurrence of the major bleeding based on a modification of the ISTH criteria were reported. Major bleeding is defined as clinically overt bleeding that is associated with a reduction in hemoglobin of 2 grams per deciliter (g/dL) or more, or a transfusion of 2 or more units of packed red blood cells or whole blood, or occurrence at a critical site defined as intracranial, intra-spinal, intraocular, pericardial, intra-articular, intra-muscular with compartment syndrome, retroperitoneal, or fatal outcome.

    Time frame: Up to Day 35

  3. Number of Participants Who Were Hospitalized or Dead on Day 35

    Number of participants who were hospitalized or dead on Day 35 were reported.

    Time frame: At Day 35 (+/- 6 days)

07

Results

Posted Jul 18, 2023
Limitations and caveats
The study was terminated prematurely due to enrollment challenges.

Participant flow

Participant flow — Overall Study
MilestoneRivaroxaban 10 Milligrams (mg)Placebo
Started641643
Treated (safety analysis set)599598
Completed640641
Not completed12
Withdrew: Withdrawal by subject12

Outcome measures

PrimaryNumber of Participants With Time to First Occurrence of Primary Efficacy Composite Endpoint

Number of participants with time to first occurrence of primary efficacy composite endpoint were reported. Time to first occurrence of primary efficacy composite endpoint is defined as time from randomization to first occurrence of any component of the primary endpoint. The components were: symptomatic venous thromboembolism (VTE), myocardial infarction (MI), ischemic stroke, acute limb ischemia, non-central nervous system (non-CNS) systemic embolization, all-cause hospitalization, and all-cause mortality.

Time frame:
Up to Day 35
Reported as:
Count of participants · Participants
Number of Participants With Time to First Occurrence of Primary Efficacy Composite Endpoint
ParticipantsRivaroxaban 10 Milligrams (mg)Placebo
Number of Participants With Time to First Occurrence of Primary Efficacy Composite Endpoint2219
Statistical analysis
  • Rivaroxaban 10 Milligrams (mg) vs Placebo · Log Rank · p = 0.626 · Cox proportional hazard: 1.16 · 95% CI 0.63 to 2.15Log rank test stratified by the time from COVID-19 positive test to randomization.
PrimaryNumber of Participants With Time to First Occurrence of The Principle Safety Outcome (Fatal Bleeding and Critical Site Bleeding) Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria

Number of participants with time to first occurrence of the principle safety outcome (fatal bleeding and critical site bleeding) based on a Modification of the ISTH criteria were reported. Fatal bleeding is defined as any bleeding event that leads to fatal outcome. Critical site bleeding defined as any bleeding event that occurred at critical site such as intracranial, intra-spinal, intraocular, pericardial, intra-articular, intra-muscular with compartment syndrome, retroperitoneal.

Time frame:
Up to Day 35
Reported as:
Count of participants · Participants
Number of Participants With Time to First Occurrence of The Principle Safety Outcome (Fatal Bleeding and Critical Site Bleeding) Based on a Modification of the International Society on Thrombosis and Haemostasis (ISTH) Criteria
ParticipantsRivaroxaban 10 Milligrams (mg)Placebo
Fatal Bleeding00
Critical Site Bleeding00
SecondaryNumber of Participants With Time to the First Occurrence of Secondary Efficacy Outcomes

Number of participants with time to the first occurrence of secondary efficacy outcomes which included thrombotic events (symptomatic VTE, myocardial infarction, ischemic stroke, acute limb ischemia, non-CNS systemic embolization), emergency room (ER) visit, all-cause mortality, all-cause hospitalization, any thrombotic outcome and all-cause mortality, and any thrombotic outcome and all-cause hospitalization, were reported.

Time frame:
From Day 1 up to Day 35
Reported as:
Count of participants · Participants
Number of Participants With Time to the First Occurrence of Secondary Efficacy Outcomes
ParticipantsRivaroxaban 10 Milligrams (mg)Placebo
Symptomatic VTE03
Myocardial Infraction00
Ischemic stroke02
Acute limb ischemia00
Non-CNS systemic embolization00
ER Visit2634
All-cause hospitalization2117
All-cause Mortality22
Any Thrombotic Outcome and All-cause Mortality27
Any Thrombotic Outcome and All-cause Hospitalization2117
SecondaryNumber of Participants With Time to First Occurrence of Major Bleeding Based on a Modification of the ISTH Criteria

Number of participants with time to first occurrence of the major bleeding based on a modification of the ISTH criteria were reported. Major bleeding is defined as clinically overt bleeding that is associated with a reduction in hemoglobin of 2 grams per deciliter (g/dL) or more, or a transfusion of 2 or more units of packed red blood cells or whole blood, or occurrence at a critical site defined as intracranial, intra-spinal, intraocular, pericardial, intra-articular, intra-muscular with compartment syndrome, retroperitoneal, or fatal outcome.

Time frame:
Up to Day 35
Reported as:
Count of participants · Participants
Number of Participants With Time to First Occurrence of Major Bleeding Based on a Modification of the ISTH Criteria
ParticipantsRivaroxaban 10 Milligrams (mg)Placebo
Number of Participants With Time to First Occurrence of Major Bleeding Based on a Modification of the ISTH Criteria10
SecondaryNumber of Participants Who Were Hospitalized or Dead on Day 35

Number of participants who were hospitalized or dead on Day 35 were reported.

Time frame:
At Day 35 (+/- 6 days)
Reported as:
Count of participants · Participants
Number of Participants Who Were Hospitalized or Dead on Day 35
ParticipantsRivaroxaban 10 Milligrams (mg)Placebo
Number of Participants Who Were Hospitalized or Dead on Day 3553

Adverse events

Collected over Adverse Event collection started from screening up to Day 49 post-treatment follow-up. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban 10 Milligrams (mg)2/641 (0.3%)1/599 (0.2%)57/599 (9.5%)
Placebo2/643 (0.3%)0/598 (0%)50/598 (8.4%)
Most frequent serious events
Most frequent serious events
EventRivaroxaban 10 Milligrams (mg)Placebo
Drug HypersensitivityImmune system disorders1/5990/598
Most frequent other events
Showing 10 of 82
Most frequent other events
EventRivaroxaban 10 Milligrams (mg)Placebo
HeadacheNervous system disorders5/5997/598
ContusionInjury, poisoning and procedural complications3/5996/598
NauseaGastrointestinal disorders2/5995/598
Abdominal Pain UpperGastrointestinal disorders5/5991/598
DiarrhoeaGastrointestinal disorders4/5991/598
Dry MouthGastrointestinal disorders4/5990/598
Muscle SpasmsMusculoskeletal and connective tissue disorders4/5993/598
DizzinessNervous system disorders4/5992/598
Covid-19Infections and infestations3/5992/598
RashSkin and subcutaneous tissue disorders3/5992/598

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rivaroxaban 10 Milligrams (mg)PlaceboTotal
Mean56.3 ± 13.0755.7 ± 13.356 ± 13.18
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban 10 Milligrams (mg)PlaceboTotal
Female399384783
Male242259501
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rivaroxaban 10 Milligrams (mg)PlaceboTotal
Hispanic or Latino9597192
Not Hispanic or Latino5205081028
Unknown or Not Reported263864
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rivaroxaban 10 Milligrams (mg)PlaceboTotal
American Indian or Alaska Native156
Asian251641
Native Hawaiian or Other Pacific Islander325
Black or African American6165126
White465464929
More than one race112
Unknown or Not Reported8590175
Region of Enrollment
Region of Enrollment(Participants)Rivaroxaban 10 Milligrams (mg)PlaceboTotal
United States6416431284
08

Study locations

17 sites
  • University of Arizona
    Tucson, Arizona 85721, United States
  • Southern California Permanente Medical Group
    Los Angeles, California 90027, United States
  • Kaiser Permanente Northern California
    Oakland, California 94612, United States
  • University of Colorado Denver
    Aurora, Colorado 80045, United States
  • Florida Hospital Orlando
    Orlando, Florida 32803, United States
  • Emory University
    Atlanta, Georgia 30308, United States
  • Morehouse School of Medicine
    Atlanta, Georgia 30310, United States
  • Atlanta VA Medical Center
    Decatur, Georgia 30033, United States
  • Northshore Universite Healthsystem
    Evanston, Illinois 60201, United States
  • Meritus Center for Clinical Research
    Hagerstown, Maryland 21742, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Lenox Hill Hospital -Northwell Health
    New York, New York 10075, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37235, United States
  • Texas Health Physicians Group
    Fort Worth, Texas 76107, United States
  • Franciscan Research Center
    Tacoma, Washington 98404, United States
09

References and documents

Publications

  • Piazza G, Spyropoulos AC, Hsia J, Goldin M, Towner WJ, Go AS, Bull TM, Weng S, Lipardi C, Barnathan ES, Bonaca MP; PREVENT-HD Investigators. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial. Circulation. 2023 Jun 20;147(25):1891-1901. doi: 10.1161/CIRCULATIONAHA.123.063901. Epub 2023 May 8. PubMed 37154020 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Jun 2022, 21 months.

Results were first posted in Jul 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2020
First posted
Aug 11, 2020
StartActual
Aug 13, 2020
Primary completionActual
Jun 1, 2022
CompletionActual
Jun 1, 2022
Results first posted
Jul 18, 2023
Last update
Jul 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04508023
Responsible party
Sponsor
First posted
Aug 11, 2020
Start date
Aug 13, 2020
Primary completion
Jun 1, 2022
Completion
Jun 1, 2022
Results posted
Jul 18, 2023
Last update
Jul 18, 2023

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion